Moreover, a high-content chemical screening based on GLIS3−/− hESCs derivatives identified a drug candidate, galunisertib, that could be used for treatment of GLIS3-associated diabetes (Amin et al., 2018). The gene discussed is GLIS3; the disease is diabetes mellitus.